Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Goserelin (Primary) ; Prednisone
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

14 Sep 2022 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
14 May 2021 Planned End Date changed from 1 Dec 2021 to 1 Aug 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com